David Denton’s appointment, effective Aug. 17, comes as the company struggles to execute a turnaround, with sales dropping in ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Pfizer said on Monday its drug for ​a type of lung cancer ‌missed the main goal of improving survival in patients compared to ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

The ruling marks the end of a case that put Alnylam and Pfizer at loggerheads. In its response to the PMCPA, Alnylam accused ...

A Pfizer executive reveals China is outpacing Europe in pharmaceutical innovation and drug development, prompting concerns ...

Pfizer said on Thursday that finance chief Dave Denton will leave ⁠on August 15 to return to the consumer goods industry.

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...